Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study.

导出 OA

翻译打印收藏纠错

作者： Maureen M,Jonas ^[1] ; Robert H,Squires ^[2] ; Susan M,Rhee ^[3] ; Chih-Wei,Lin ^[4] ; Kazuhiko,Bessho ^[5] ; Cornelia,Feiterna-Sperling ^[6] ; Loreto,Hierro ^[7] ; Deirdre,Kelly ^[8] ; Simon C,Ling ^[9] ; Tatiana,Strokova ^[10] ; Antonio,Del Valle-Segarra ^[11] ; Sandra,Lovell ^[12] ; Wei,Liu ^[13] ; Teresa I,Ng ^[5] ; Ariel,Porcalla ^[5] ; Yuri Sanchez,Gonzalez ^[5] ; Margaret,Burroughs ^[5] ; Etienne,Sokal ^[5]

作者单位： Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA. ^[1] Department of Pediatrics, Harvard Medical School, Boston, MA. ^[2] Division of Gastroenterology, Hepatology, and Nutrition, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA. ^[3] Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA. ^[4] AbbVie Inc., North Chicago, IL. ^[5] Amgen Inc., Thousand Oaks, CA. ^[6] Osaka University Hospital, Osaka, Japan. ^[7] Charité - Universitaetsmedizin Berlin, Berlin, Germany. ^[8] Hospital Universitario La Paz, Madrid, Spain. ^[9] Birmingham Women's & Children's Hospital, Birmingham, United Kingdom. ^[10] Division of Gastroenterology, Hepatology & Nutrition, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada. ^[11] Federal Research Centre of Nutrition and Biotechnology, Moscow, Russian Federation. ^[12] San Jorge Children's Hospital, San Juan, Puerto Rico. ^[13] Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. ^[14]